Cited by 574Traumatic Brain Injury and Neurovascular DisturbancesTraumatic Brain Injury ResearchAutomotive and Human Injury Biomechanics

Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies

Open access
Loane, David J., Faden, Alan I.·2010·Trends in Pharmacological Sciences

Abstract

Traumatic brain injury (TBI) causes secondary biochemical changes that contribute to subsequent tissue damage and associated neuronal cell death. Neuroprotective treatments that limit secondary tissue loss and/or improve behavioral outcome have been well established in multiple animal models of TBI. However, translation of such neuroprotective strategies to human injury have been disappointing, with the failure of more than thirty controlled clinical trials. Both conceptual issues and methodological differences between preclinical and clinical injury have undoubtedly contributed to these translational difficulties. More recently, changes in experimental approach, as well as altered clinical trial methodologies, have raised cautious optimism regarding the outcomes of future clinical trials. Here we critically review developing experimental neuroprotective strategies that show promise, and we propose criteria for improving the probability of successful clinical translation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tips.2010.09.005

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The failure of pre-clinical TBI therapies to translate has been attributed in part to inadequate preclinical efforts to recapitulate the complexity of the human injury.

    “This has been attributed in part to inadequate preclinical efforts to recapitulate the complexity of the human injury.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Loane, D. J., & Faden, A. I.
Affiliations
University of Maryland, Baltimore (US)
Corresponding author
Faden, Alan I.
Venue
Trends in Pharmacological Sciences
Publisher
Elsevier BV
Published
2010-12
Volume
31
Issue
12
Pages
596-604
ISSN
0165-6147 (ISSN-L)
OpenAlex
W2073814752
Cited by
574
References
118
Citations by year
2026: 19 · 2025: 16 · 2024: 46 · 2023: 24 · 2022: 27 · 2021: 47 · 2020: 51 · 2019: 34 · 2018: 42 · 2017: 51 · 2016: 41 · 2015: 41 · 2014: 47 · 2013: 36 · 2012: 33
FWCI
3.53
Type
journal article
Language
en
Open access
Locations
  • Trends in Pharmacological Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Neurological Disorders and Stroke (R01NS037313, R01NS061839, R01NS052568)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (RC1HD064758)
Topics
  • Health Sciences › Medicine › Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Health Sciences › Medicine › Epidemiology › Traumatic Brain Injury Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Automotive and Human Injury Biomechanics
Keywords
traumatic brain injury, neuroprotection, secondary brain injury, neuronal cell death, translational research, clinical trial failure, animal models of TBI, clinical trial design
MeSH terms
Animals, Brain, Brain Injuries, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Nerve Degeneration, Drugs, Investigational, Drug Delivery Systems, Neuroprotective Agents, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review